ALS due to a novel TBK1 mutation in Brazil.

Amyotroph Lateral Scler Frontotemporal Degener

Departamento de Neurociências, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.

Published: November 2022

TANK-binding kinase 1 (TBK1) gene mutations cause ALS and frontotemporal dementia (FTD). We report a novel TBK1 mutation in a Brazilian patient with ALS. Symptoms started at age 44 (lower-limb onset). Despite treatment with riluzole, his condition progressed over 5 years to aphemia, dysphagia, gastrostomy and tracheostomy. A diagnostic test panel for neurodegenerative disorders disclosed a novel likely pathogenic heterozygous intronic mutation in the TBK1 gene: c.1189 + 1G > T (Splice donor), intron 9. This mutation is expected to disrupt RNA splicing and lead to loss of protein function. Disruption of this splice site has been observed in patients with TBK1-related disorders. Separate and additional C9ORFF72 testing was negative. To our knowledge, this is the second patient with a TBK1 mutation (novel splice donor intronic mutation) reported in Brazil, and the first to include a full description of the clinical course. Further studies are necessary to establish the frequency of TBK1 mutations in Brazilian ALS patients (and worldwide) and to evaluate the possible different clinical phenotypes and the disease course.

Download full-text PDF

Source
http://dx.doi.org/10.1080/21678421.2022.2028169DOI Listing

Publication Analysis

Top Keywords

tbk1 mutation
12
novel tbk1
8
tbk1 gene
8
intronic mutation
8
splice donor
8
tbk1
6
mutation
6
als
4
als novel
4
mutation brazil
4

Similar Publications

Heme is known to bind to the intrinsically disordered region (IDR) to regulate protein function. The binding of heme to the IDR of transcription factor BACH2 promotes plasma cell differentiation, but the molecular basis is unknown. Heme was found to increase BACH2 IDR interaction with TANK-binding kinase 1 (TBK1).

View Article and Find Full Text PDF
Article Synopsis
  • Endometrial cancer is a serious gynecological issue, and the study focused on the role of TBK1, a kinase involved in inflammation and immunity, in this cancer type.
  • Research found that low TBK1 expression is linked to better patient outcomes, and inhibiting TBK1 with amlexanox reduced cancer cell growth and migration.
  • The effects of amlexanox were shown to work through the AKT/NF-κB signaling pathway, suggesting a new direction for cancer treatments targeting TBK1 in endometrial cancer.
View Article and Find Full Text PDF

Amyotrophic lateral sclerosis (ALS) is a devastating, uniformly lethal degenerative disease of motor neurons, presenting with relentlessly progressive muscle atrophy and weakness. More than fifty genes carrying causative or disease-modifying variants have been identified since the 1990s, when the first ALS-associated variant in the gene SOD1 was discovered. The most commonly mutated ALS genes in the European populations include the C9orf72, SOD1, TARDBP and FUS.

View Article and Find Full Text PDF
Article Synopsis
  • Macroautophagy involves creating structures called autophagosomes for cellular cleanup, and disrupting their closure has unknown effects.
  • Researchers created mice with a specific mutation that impairs autophagosome closure, resulting in various issues like protein buildup and growth problems, though some survive into adulthood.
  • The study found that this mutation causes the buildup of a protein (TBK1) on forming autophagosomes, leading to increased phosphorylation and aggregation of other proteins, suggesting a new role for these structures in managing cellular waste.
View Article and Find Full Text PDF

Targeting ATAD3A Phosphorylation Mediated by TBK1 Ameliorates Senescence-Associated Pathologies.

Adv Sci (Weinh)

January 2025

Guangdong Cardiovascular Institute, Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.

Targeting cellular senescence, one of the hallmarks of aging and aging-related pathologies emerges as an effective strategy for anti-aging and cancer chemotherapy. Here, a switch from TBK1-OPTN axis to TBK1-ATAD3A axis to promote cellular senescence is shown. Mechanically, TBK1 protein is abnormally activated and localized to the mitochondria during senescence, which directly phosphorylates ATAD3A at Ser321.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!